170 related articles for article (PubMed ID: 36240831)
21. SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey.
Murhekar MV; Bhatnagar T; Selvaraju S; Saravanakumar V; Thangaraj JWV; Shah N; Kumar MS; Rade K; Sabarinathan R; Asthana S; Balachandar R; Bangar SD; Bansal AK; Bhat J; Chopra V; Das D; Deb AK; Devi KR; Dwivedi GR; Khan SMS; Kumar CPG; Kumar MS; Laxmaiah A; Madhukar M; Mahapatra A; Mohanty SS; Rangaraju C; Turuk A; Baradwaj DK; Chahal AS; Debnath F; Haq I; Kalliath A; Kanungo S; Kshatri JS; Lakshmi GGJN; Mitra A; Nirmala AR; Prasad GV; Qurieshi MA; Sahay S; Sangwan RK; Sekar K; Shukla VK; Singh PK; Singh P; Singh R; Varma DS; Viramgami A; Panda S; Reddy DCS; Bhargava B;
Lancet Glob Health; 2021 Mar; 9(3):e257-e266. PubMed ID: 33515512
[TBL] [Abstract][Full Text] [Related]
22. Seroprevalence of antibodies to measles and rubella eight months after a vaccination campaign in the southeast of Iran.
Izadi S; Zahraei SM; Mokhtari-Azad T
Hum Vaccin Immunother; 2018 Jun; 14(6):1412-1416. PubMed ID: 29420120
[TBL] [Abstract][Full Text] [Related]
23. Leveraging a national biorepository in Zambia to assess measles and rubella immunity gaps across age and space.
Carcelen AC; Winter AK; Moss WJ; Chilumba I; Mutale I; Chongwe G; Monze M; Mulundu G; Nkamba H; Mwansa FD; Mulenga L; Rhoda DA; Hayford K; Mutembo S
Sci Rep; 2022 Jun; 12(1):10217. PubMed ID: 35715547
[TBL] [Abstract][Full Text] [Related]
24. Use of the revised World Health Organization cluster survey methodology to classify measles-rubella vaccination campaign coverage in 47 counties in Kenya, 2016.
Subaiya S; Tabu C; N'ganga J; Awes AA; Sergon K; Cosmas L; Styczynski A; Thuo S; Lebo E; Kaiser R; Perry R; Ademba P; Kretsinger K; Onuekwusi I; Gary H; Scobie HM
PLoS One; 2018; 13(7):e0199786. PubMed ID: 29965975
[TBL] [Abstract][Full Text] [Related]
25. Burden of congenital rubella syndrome (CRS) in India based on data from cross-sectional serosurveys, 2017 and 2019-20.
Shanmugasundaram D; Awasthi S; Dwibedi B; Geetha S; Jain M; Malik S; Patel B; Singh H; Tripathi S; Viswanathan R; Agarwal A; Bonu R; Jain S; Jena SK; Priyasree J; Pushpalatha K; Ali S; Biswas D; Jain A; Narang R; Madhuri S; George S; Kaduskar O; Kiruthika G; Sabarinathan R; Sapakal G; Gupta N; Murhekar MV
PLoS Negl Trop Dis; 2021 Jul; 15(7):e0009608. PubMed ID: 34297716
[TBL] [Abstract][Full Text] [Related]
26. A 16-year review of seroprevalence studies on measles and rubella.
Dimech W; Mulders MN
Vaccine; 2016 Jul; 34(35):4110-4118. PubMed ID: 27340097
[TBL] [Abstract][Full Text] [Related]
27. Status of coverage of MR vaccination, after supplementary immunization activities in a rural area of South India: a rapid immunization coverage survey.
Newtonraj A; Vincent A; Selvaraj K; Manikandan M
Rural Remote Health; 2019 Sep; 19(3):5261. PubMed ID: 31529972
[TBL] [Abstract][Full Text] [Related]
28. Measles-Rubella Supplementary Immunization Activity Readiness Assessment - India, 2017-2018.
Gurnani V; Haldar P; Khanal S; Bhatnagar P; Singh B; Ahmed D; Samiuddin M; Kumar A; Negi Y; Gupta S; Harvey P; Bahl S; Dabbagh A; Alexander JP; Goodson JL
MMWR Morb Mortal Wkly Rep; 2018 Jul; 67(26):742-746. PubMed ID: 29975677
[TBL] [Abstract][Full Text] [Related]
29. Vaccination coverage survey and seroprevalence among forcibly displaced Rohingya children, Cox's Bazar, Bangladesh, 2018: A cross-sectional study.
Feldstein LR; Bennett SD; Estivariz CF; Cooley GM; Weil L; Billah MM; Uzzaman MS; Bohara R; Vandenent M; Adhikari JM; Leidman E; Hasan M; Akhtar S; Hasman A; Conklin L; Ehlman D; Alamgir A; Flora MS
PLoS Med; 2020 Mar; 17(3):e1003071. PubMed ID: 32231368
[TBL] [Abstract][Full Text] [Related]
30. Challenges Addressing Inequalities in Measles Vaccine Coverage in Zambia through a Measles-Rubella Supplementary Immunization Activity during the COVID-19 Pandemic.
Yang Y; Kostandova N; Mwansa FD; Nakazwe C; Namukoko H; Sakala C; Bobo P; Masumbu PK; Nachinga B; Ngula D; Carcelen AC; Prosperi C; Winter AK; Moss WJ; Mutembo S
Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992192
[TBL] [Abstract][Full Text] [Related]
31. Rubella and measles seroprevalence among women of childbearing age, Argentina, 2002.
Dayan GH; Panero MS; Urquiza A; Molina M; Prieto S; Del Carmen Perego M; Scagliotti G; Galimberti D; Carroli G; Wolff C; Bi D; Bellini W; Icenogle J; Reef S
Epidemiol Infect; 2005 Oct; 133(5):861-9. PubMed ID: 16181506
[TBL] [Abstract][Full Text] [Related]
32. Seroprevalence of measles and rubella antibodies in pregnant women Haiti, 2012.
Fitter DL; Anselme R; Paluku G; Rey G; Flannery B; Tohme RA; Marston BJ; Griswold M; Boncy J; Vertefeuille JF
Vaccine; 2013 Dec; 32(1):69-73. PubMed ID: 24188751
[TBL] [Abstract][Full Text] [Related]
33. [Immunity coverage against measles, rubella and parotiditis viruses in a juvenile population in Leon, Spain].
Suárez J; Castañeda MR; Gutiérrez CB; Rodríguez Barbosa JI; Tascón RI; Rodríguez Ferri EF
Med Clin (Barc); 1993 Oct; 101(13):484-7. PubMed ID: 8231381
[TBL] [Abstract][Full Text] [Related]
34. Comparison of population-based measles-rubella immunoglobulin G antibody prevalence between 2014 and 2019 in Lao People's Democratic Republic: Impacts of the national immunization program.
Miyano S; Vynnycky E; Pattamavone C; Ichimura Y; Mori Y; Nouanthong P; Phounphenghack K; Tengbriacheu C; Khamphaphongphane B; Franzel L; Yang TU; Raaijimarkers H; Komada K; Ota T; Funato M; Takeda M; Hachiya M
Int J Infect Dis; 2023 Apr; 129():70-77. PubMed ID: 36758852
[TBL] [Abstract][Full Text] [Related]
35. Seroprevalence of measles-, mumps- and rubella-specific IgG antibodies in German children and adolescents and predictors for seronegativity.
Poethko-Müller C; Mankertz A
PLoS One; 2012; 7(8):e42867. PubMed ID: 22880124
[TBL] [Abstract][Full Text] [Related]
36. Factors affecting non-coverage of measles-rubella vaccination among children aged 9-59 months in Tanzania.
Mkopi A; Mtenga S; Festo C; Mhalu G; Shabani J; Tillya R; Masemo A; Kheir K; Nassor M; Mwengee W; Lyimo D; Masanja H
Vaccine; 2021 Oct; 39(41):6041-6049. PubMed ID: 34531077
[TBL] [Abstract][Full Text] [Related]
37. Australian rubella serosurvey 2012-2013: On track for elimination?
Edirisuriya C; Beard FH; Hendry AJ; Dey A; Gidding HF; Hueston L; Dwyer DE; Wood JG; Macartney KK; McIntyre PB
Vaccine; 2018 May; 36(20):2794-2798. PubMed ID: 29661586
[TBL] [Abstract][Full Text] [Related]
38. Impact of an Intervention to Use a Measles, Rubella, and Polio Mass Vaccination Campaign to Strengthen Routine Immunization Services in Nepal.
Wallace AS; Bohara R; Stewart S; Subedi G; Anand A; Burnett E; Giri J; Shrestha J; Gurau S; Dixit S; Rajbhandari R; Schluter WW
J Infect Dis; 2017 Jul; 216(suppl_1):S280-S286. PubMed ID: 28838201
[TBL] [Abstract][Full Text] [Related]
39. Integrating Blood Collection within Household Surveys: Lessons Learned from Nesting a Measles and Rubella Serological Survey within a Post-Campaign Coverage Evaluation Survey in Southern Province, Zambia.
Mutembo S; Carcelen A; Mwansa FD; Searle K; Wanyiri JW; Book C; Thuma PE; Moss WJ; Hayford K
Am J Trop Med Hyg; 2018 Dec; 99(6):1639-1642. PubMed ID: 30277204
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of vaccination coverage of measles-rubella campaign in Imphal East District, Manipur: A cross-sectional study.
Rajkumari B; Keisam A; Haobam DS; Thounaojam T
Indian J Public Health; 2020; 64(2):173-177. PubMed ID: 32584301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
